External Quality Assurance (EQA) of G6PD Quantitative Test

Survey No. : RH2017-04 Sample sent on : 2017/10/16 Reporting deadline : 2017/10/23
Sample sent : 19 set Results reported (%) : 19 (100%)

1.Summary report on this EQA survey 4.Long term observation of inter laboratory CV vs. surveys
2.The distribution of G6PD reported in this survey 5.Long term observation of inter laboratory CV vs. G6PD activities
3.The distribution of Hb reported in this survey 6.Deviation graph for individual laboratory

Summary Report of G6PD and Hemoglobin (Hb) Quantitative Test Results

Lab Referral
Hosp.		 Report
(day)		 Sample 1 Sample 2 Sample 3 Hb 1 Hb 2 Hb 3
(U/gHb) D% z score SDI (U/gHb) D% z score SDI (U/gHb) D% z score SDI (g/dL) (g/dL) (g/dL)
RH01 RH01 1 12.2 -2.4% -0.3 -0.6 4.7 -2.1% -0.3 -0.4 2.4 -11.1% -1.4 -0.6 2.3 2.5 2.2
RH02 RH02 1 11.8 -5.6% -0.8 -1.2 4.9 2.1% 0.3 0.4 2.9 7.4% 0.9 0.9 2.2 2.3 2.0
RH04 RH04 7 12.2 -2.4% -0.3 -0.6 4.6 -4.2% -0.6 -0.7 2.7 0.0% 0.0 0.3 2.0 2.3 2.0
RH05 RH05 3 13.5 8.0% 1.1 1.3 5.5 14.6% 2.1 2.6 3.1 14.8% 1.8 1.5 2.2 2.3 2.1
RH06 RH06 4 11.7 -6.4% -0.9 -1.3 4.8 0.0% 0.0 0.0 2.4 -11.1% -1.4 -0.6 1.8 1.9 1.6
RH07 RH07
A0189		 4 13.0 4.0% 0.6 0.6 5.0 4.2% 0.6 0.7 3.0 11.1% 1.4 1.2 2.1 2.2 1.9
RH08 RH08 4 12.7 1.6% 0.2 0.1 4.8 0.0% 0.0 0.0 2.6 -3.7% -0.5 0.0 2.1 2.2 1.9
RH09 RH09 2 12.6 0.8% 0.1 0.0 4.6 -4.2% -0.6 -0.7 2.6 -3.7% -0.5 0.0 2.1 2.3 2.0
RH10 RH10 4 13.4 7.2% 1.0 1.2 5.1 6.3% 0.9 1.1 2.8 3.7% 0.5 0.6 2.2 2.3 2.1
RH12 RH12 7 12.3 -1.6% -0.2 -0.4 4.6 -4.2% -0.6 -0.7 2.5 -7.4% -0.9 -0.3 2.1 2.2 1.9
RH13 RH13 3 13.0 4.0% 0.6 0.6 5.5 14.6% 2.1 2.6 3.0 11.1% 1.4 1.2 2.3 2.3 2.0
RH14 RH14 2 11.7 -6.4% -0.9 -1.3 4.8 0.0% 0.0 0.0 2.5 -7.4% -0.9 -0.3 2.1 2.3 2.0
RH19 RH19 7 12.1 -3.2% -0.5 -0.7 4.2 -12.5% -1.8 -2.2 2.1 -22.2% -2.8 -1.5 2.1 2.2 1.9
A0203 RH18
A0203		 7 13.2 5.6% 0.8 0.9 4.7 -2.1% -0.3 -0.4 2.7 0.0% 0.0 0.3 2.2 2.4 2.0
G026 G026 3 12.3 -1.6% -0.2 -0.4 5.0 4.2% 0.6 0.7 3.2 18.5% 2.3 1.8 2.1 2.2 1.9
CL001 RH16 7 12.5 0.0% 0.0 -0.1 4.7 -2.1% -0.3 -0.4 2.3 -14.8% -1.8 -0.9 2.2 2.3 2.0
CL002 RH03
RH11
RH17
G031
B005
CL016
A0511		 7 13.5 8.0% 1.1 1.3 5.0 4.2% 0.6 0.7 2.7 0.0% 0.0 0.3 2.0 2.2 1.8
CL014 CL014 5 12.2 -2.4% -0.3 -0.6 4.5 -6.3% -0.9 -1.1 1.6 -40.7% -5.0 -2.9 2.1 2.1 1.9
CL015B CL015B 3 13.1 4.8% 0.7 0.7 5.0 4.2% 0.6 0.7 2.7 0.0% 0.0 0.3 2.1 2.3 1.9
      Total participating laboratories = 19
Xa (Median) - 4 12.5 4.8 2.7 2.1 2.3 2.0
uXa - - 0.169 0.068 0.086 - - -
σp - - 0.875 0.336 - - - -
σp′ - - - - 0.218 - - -
Range - 1-7 11.7-13.5 4.2-5.5 1.6-3.2 1.8-2.3 1.9-2.5 1.6-2.2
n - - 19 19 19 19 19 19
Mean - - 12.6 4.8 2.6 2.1 2.3 2.0
S.D. - - 0.67 0.27 0.34 0.10 0.09 0.10
C.V. - - 5.3% 5.6% 13.1% 4.8% 3.9% 5.0%
Note:
1. D% = [ ( X - Xa ) / Xa ] x 100% ; X = Your Results , Xa = Assigned value
2. uXa = uncertainty of the assigned value. uXa = 1.1 x SD / n1/2
3. SD for proficiency assessment ( σp ) = 7% x Xa ; but while Xa < 2.9 U/gHb, σp = 0.2 U/gHb
4. Adjusted SD for proficiency assessment ( σp′ ) = ( σp2 + uXa2 )1/2. σp′ is used for proficiency assessment when uXa ≥ 0.3σp
5. z score = D /σp ; D = X - Xa, σp = SD for proficiency assessment
6. SDI = ( X - Mean ) / SD ; SD = standard deviation of peer group ; SDI is not calculated when SD equals 0
7. The assigned value ( Xa ) is the median of all the results reported of this EQA sample
8. Robust results ( Mean and SD ) were calculated by Algorithm A according to ISO 13528
9. The evaluation criteria for measurement result of each specimen : Acceptable : | z | <= 2; Caution : 2 < | z | <= 3; Unsatisfactory : | z | > 3
10. Maximum Allowable Deviation ( MAD ) = 3 x ( σp / Xa ) x 100% or 3 x ( σp′ / Xa ) x 100% when uXa ≥ 0.3 σp

Ordered by Referral Hosp.

Newborn Screening QA Program

Preventive Medicine Foundation

Newborn Screening Reference Center

National Institutes of Health

P.O. Box 624, Taipei Xinwei, Taipei City 10699, Taiwan University of the Philippines  
Tel : + 886-2-2703-6080; Fax : +886-2-2703-6070   625 Pedro Gil St., Ermita, Manila 1000, Philippines  
  Fax : + 632-522-4396;  
         
updated : 24 Oct, 2017    

[HOME]